Talking With Titans

Clozapine Remains Underused After REMS Elimination: A Conversation With Jose Rubio, MD, PhD

ByJohn J. Miller, MD,Jose M. Rubio, MD, PhD

October 8th 2026

Ending the REMS cut the paperwork, but reimbursement that ignores clozapine’s added care demands still keeps the drug from patients who could benefit.

AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD

ByJohn J. Miller, MD,Christoph U. Correll, MD

October 3rd 2026

AI should take over burdensome tasks, not clinicians, and guardrails must stop decision support systems from guessing.

Esketamine, Off-Label Ketamine, and the Regulatory Gap: A Conversation With Lisa Harding, MD

ByJohn J. Miller, MD,Lisa Harding, MD

October 2nd 2026

An esketamine expert reflects on 7 years of nasal spray use and asks why racemic ketamine faces none of the same rules.

History and Future of ECT, With John J. Miller, MD, and Michael Henry, MD

ByJohn J. Miller, MD,Michael E. Henry, MD

June 1st 2026

Review the origins and advancements of ECT.

Effect Size Magic: A Conversation With Leslie L. Citrome, MD, MPH

ByJohn J. Miller, MD,Leslie L. Citrome, MD, MPH

May 28th 2026

ASCP awardee Leslie Citrome explains why effect size, NNT, and NNH beat P-values, helping clinicians choose treatments tailored to each patient.

Transdiagnostic Anhedonia: A Conversation With Roger S. McIntyre, MD, FRCPC

ByJohn J. Miller, MD,Roger S. McIntyre, MD, FRCPC

May 27th 2026

Clinicians explore transdiagnostic anhedonia—reward learning, loneliness, and digital rewards—offering practical ideas to personalize treatment.

Engaging With Patients With Acute Psychosis: A Conversation With Peter J. Weiden, MD

ByJohn J. Miller, MD,Peter J. Weiden, MD

May 26th 2026

ASCP 2026 leaders share practical ways to engage patients in acute psychosis—active listening, noncollusive language, and rapport before assessment.

Delirium Treatment and Prevention Guidelines: Discussion With Mark Oldham, MD, and John J Miller, MD

ByMark Oldham, MD,John J. Miller, MD

December 9th 2025

Explore the complexities of delirium and its neuropsychiatric disturbances, highlighting innovative treatment approaches and the latest research insights.

Current Use of Antipsychotic Medications: A Conversation With Phillip R. Muskin, MD

ByJohn J. Miller, MD,Philip R. Muskin, MD, MA, DLFAPA, LFACLP

May 27th 2025

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

Developing a Small Molecule With Lithium's Benefits, But Not its Baggage: A Conversation With Jonathan M. Meyer, MD, DLFAPA

ByJohn J. Miller, MD,Jonathan M. Meyer, MD, DLFAPA

May 22nd 2025

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

Insulin Is an Antidepressant: A Conversation With Roger McIntyre, MD, FRCPC

ByJohn J. Miller, MD,Roger S. McIntyre, MD, FRCPC

May 22nd 2025

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

A Shift in the Way We Think About the Biology of Depression: A Conversation With John H. Krystal, MD

ByJohn J. Miller, MD,John H. Krystal, MD

May 21st 2025

Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.

Assessing Adult ADHD: A Conversation With Jeffrey Newcorn, MD

ByJohn J. Miller, MD,Jeffrey Newcorn, MD

May 21st 2025

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

Use of Plasma Levels of Antipsychotics: A Conversation With Jonathan M. Meyer, MD, DLFAPA

ByJohn J. Miller, MD,Jonathan M. Meyer, MD, DLFAPA

May 21st 2025

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

Talking With Titans

Clozapine Remains Underused After REMS Elimination: A Conversation With Jose Rubio, MD, PhD

AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD

Esketamine, Off-Label Ketamine, and the Regulatory Gap: A Conversation With Lisa Harding, MD

History and Future of ECT, With John J. Miller, MD, and Michael Henry, MD

Effect Size Magic: A Conversation With Leslie L. Citrome, MD, MPH

Transdiagnostic Anhedonia: A Conversation With Roger S. McIntyre, MD, FRCPC

Engaging With Patients With Acute Psychosis: A Conversation With Peter J. Weiden, MD

Delirium Treatment and Prevention Guidelines: Discussion With Mark Oldham, MD, and John J Miller, MD

Current Use of Antipsychotic Medications: A Conversation With Phillip R. Muskin, MD

Developing a Small Molecule With Lithium's Benefits, But Not its Baggage: A Conversation With Jonathan M. Meyer, MD, DLFAPA

Insulin Is an Antidepressant: A Conversation With Roger McIntyre, MD, FRCPC

A Shift in the Way We Think About the Biology of Depression: A Conversation With John H. Krystal, MD

Assessing Adult ADHD: A Conversation With Jeffrey Newcorn, MD

Use of Plasma Levels of Antipsychotics: A Conversation With Jonathan M. Meyer, MD, DLFAPA

Trending on Psychiatric Times

The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists

ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function

New Phase 2 Data on Bezisterim for the Treatment of Long COVID

When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice

What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?